SQLite Web: event_store.db

Could not fetch row with primary-key sig_f37a7a46bcbb.

Could not fetch row with primary-key sig_29e4d8d29422.

Could not fetch row with primary-key sig_53e6456e477e.

Could not fetch row with primary-key sig_afa5a22c8afb.

Update row sig_c7013df3fa6b in signals

id

Primary key. TEXT

event_id

TEXT NOT NULL

watcher_id

TEXT

signal_type

TEXT NOT NULL

value

{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001680739-26-000005.txt","as_of":"2026-04-17T02:13:18.114675+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001680739-26-000005.txt","company":"Travere Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001680739-26-000005.txt","article_chars":2718,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_480921d2fc6a0bbe","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001680739-26-000005.txt","content_type":"text/plain","enriched_at":"2026-04-17T06:22:36.860968+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001680739-26-000005.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001680739-26-000005.txt","source_event_id":"evt_40f74188b6e6","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"eecef4809f942f3d","kind":"sec_filing","published_at":"20260416","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-16","2026-04-14","2025-11-17","2029-05-08","2030-05-15","2031-05-14","2032-05-11","2033-05-17"],"entities":[{"asset_class":"equity","name":"Travere Therapeutics, Inc.","relevance":"high","symbol":"TVTX","type":"issuer"},{"asset_class":"equity","name":"Roy D. Baynes","relevance":"high","symbol":"","type":"reporting_owner"},{"asset_class":"equity","name":"Elizabeth E. Reed","relevance":"medium","symbol":"","type":"signatory_attorney_in_fact"}],"event_type":"listing","information_gaps":["What changed vs prior known state is not provided in the signal; only the new Form 4 filing content is shown.","The cleaned text does not explicitly provide a total share count or aggregate proceeds; only line-item quantities/prices are partially visible.","The filing\u2019s exact transaction code meanings (e.g., 'M' vs 'S') are not defined in the provided text.","No explicit narrative of whether this is a sale vs other transaction types beyond the statement that it consists of sale of shares underlying stock options."],"key_facts":["SEC filing: Form 4 (CONFORMED SUBMISSION TYPE: 4).","Issuer: Travere Therapeutics, Inc. (TVTX).","Reporting owner: Baynes Roy D. (REPORTING-OWNER: OWNER DATA: Baynes Roy D.).","Filing date (filed as of date): 2026-04-16; period of report (CONFORMED PERIOD OF REPORT): 2026-04-14.","The filing states the sale was made pursuant to a written plan adopted on November 17, 2025, meeting Rule 10b5-1(c) requirements.","The filing states the transaction consists of the sale of shares underlying stock options granted to the reporting person.","The filing states the stock option is fully vested and exercisable.","Multiple lines indicate Common Stock transactions on 2026-04-14 with quantities and prices (e.g., 8,000 @ 17.94; 9,000 @ 15.43; 4,500 @ 18.27; 4,500 @ 21.38; 6,750 @ 17.11; additional entries marked 'S' with quantities and prices).","Option-related entries show expiration dates (e.g., 2029-05-08, 2030-05-15, 2031-05-14, 2032-05-11, 2033-05-17) tied to stock option (right to buy) and strike/price values (e.g., 17.94, 15.43, 18.27, 21.38, 17.11)."],"numeric_claims":[{"label":"Shares quantity (example)","value":"8000"},{"label":"Sale price per share (example)","value":"17.94"},{"label":"Plan adoption date","value":"2025-11-17"},{"label":"Filing date","value":"2026-04-16"},{"label":"Period of report","value":"2026-04-14"}],"primary_claim":"Form 4 filed 2026-04-16 by Travere Therapeutics, Inc. reports sales of shares underlying fully vested and exercisable stock options by Roy D. Baynes under a Rule 10b5-1(c) plan adopted on 2025-11-17.","relevance_score":0.55,"sentiment":"neutral","source_quality":"high","summary":"Travere Therapeutics, Inc. (TVTX) filed a Form 4 on 2026-04-16 covering transactions by reporting owner Roy D. Baynes. The filing states the sales were made under a Rule 10b5-1(c) plan and relate to shares underlying fully vested, exercisable stock options.","topics":["SEC Form 4","insider transaction","Rule 10b5-1(c) plan","stock options","common stock sales"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 Travere Therapeutics, Inc. \u00b7 Filed 20260416","ticker":"TVTX","tickers":["TVTX"],"title":"TVTX filed 4","url":"https://www.sec.gov/Archives/edgar/data/1438533/0001680739-26-000005.txt"}

TEXT NOT NULL

threshold

TEXT

direction

TEXT

severity

TEXT

window

TEXT

source

TEXT NOT NULL

reason_trace

TEXT

dedupe_key

TEXT NOT NULL

throttle_s

INTEGER (default 0

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel